Skip to main content .

Now Open: 2018 BARDA Broad Agency Announcement


BARDA Broad Agency Announcement for Advanced Research and Development of Medical Countermeasures for Pandemic Influenza, Infectious Diseases, and Chemical, Biological, Radiological and Nuclear Threats.

Click here for BAA text on beta.sam.gov

BARDA is soliciting proposals for the advanced research and development of medical countermeasures (MCM) such as vaccines, therapeutics, diagnostics, and devices. The rolling BAA-18-100-SOL-00003 has been open since 2017 and continues to receive updates to best support BARDA’s mission.

BAA-18-100-SOL-00003 aims for advanced research and development of MCMs for chemical, biological, radiological, nuclear agents, pandemic influenza, and emerging infectious diseases.

BARDA supports advanced research and development of medical countermeasures and is a component of the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE). Funding through these BAAs will be evaluated with respect to their relevance to medical countermeasure priorities as laid out in the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, 2016 PHEMCE Strategy and Implementation Plan, HHS Pandemic Influenza Plan: 2017 Update, the 2010 HHS Public Health Emergency Medical Countermeasures Enterprise Review, and the BARDA Strategic Plan 2011-2016. BARDA anticipates that advanced research and development contracts awarded under these BAAs will advance the maturity and scientific understanding of candidate medical countermeasures, and result in a broader portfolio of products for potential consideration under future procurement activities.

contentImage

Website Refresh

www.medicalcountermeasures.gov is pleased to announce a phased launch of our newly redesigned public website. We are making website improvements to provide a more modern and customer-centric web experience. Over the next several months you will see differences throughout the site while we continue implementing updates. Thank you for your understanding and please let us know if you have any questions: mailto:techwatchinbox@hhs.gov